Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

Nicholas L M Cruden; Fraser N Witherow; David J Webb; Keith A A Fox; David E Newby

doi:10.1161/01.ATV.0000129331.21092.1d

Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

Nicholas L M Cruden, Fraser N Witherow, David J Webb, Keith A A Fox, David E Newby

Research output: Contribution to journal › Article › peer-review

Abstract

Bradykinin is an endogenous vasodilator that may contribute to the systemic effects of angiotensin-converting enzyme (ACE) inhibitor therapy. Using B9340, a bradykinin receptor antagonist, we determined the contribution of bradykinin to the systemic hemodynamic effects of long-term ACE inhibition in patients with chronic heart failure.

Original language	English
Pages (from-to)	1043-8
Number of pages	6
Journal	Arteriosclerosis, Thrombosis, and Vascular Biology
Volume	24
Issue number	6
DOIs	https://doi.org/10.1161/01.ATV.0000129331.21092.1d
Publication status	Published - 22 Apr 2004

Access to Document

10.1161/01.ATV.0000129331.21092.1d

Cite this

@article{c99ea9df2dff4d86a38ab01c0714341d,

title = "Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure",

abstract = "Bradykinin is an endogenous vasodilator that may contribute to the systemic effects of angiotensin-converting enzyme (ACE) inhibitor therapy. Using B9340, a bradykinin receptor antagonist, we determined the contribution of bradykinin to the systemic hemodynamic effects of long-term ACE inhibition in patients with chronic heart failure.",

author = "Cruden, {Nicholas L M} and Witherow, {Fraser N} and Webb, {David J} and Fox, {Keith A A} and Newby, {David E}",

year = "2004",

month = apr,

day = "22",

doi = "10.1161/01.ATV.0000129331.21092.1d",

language = "English",

volume = "24",

pages = "1043--8",

journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",

issn = "1079-5642",

publisher = "Lippincott Williams & Wilkins",

number = "6",

}

Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. / Cruden, Nicholas L M; Witherow, Fraser N; Webb, David J et al.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 24, No. 6, 22.04.2004, p. 1043-8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

AU - Cruden, Nicholas L M

AU - Witherow, Fraser N

AU - Webb, David J

AU - Fox, Keith A A

AU - Newby, David E

PY - 2004/4/22

Y1 - 2004/4/22

N2 - Bradykinin is an endogenous vasodilator that may contribute to the systemic effects of angiotensin-converting enzyme (ACE) inhibitor therapy. Using B9340, a bradykinin receptor antagonist, we determined the contribution of bradykinin to the systemic hemodynamic effects of long-term ACE inhibition in patients with chronic heart failure.

AB - Bradykinin is an endogenous vasodilator that may contribute to the systemic effects of angiotensin-converting enzyme (ACE) inhibitor therapy. Using B9340, a bradykinin receptor antagonist, we determined the contribution of bradykinin to the systemic hemodynamic effects of long-term ACE inhibition in patients with chronic heart failure.

U2 - 10.1161/01.ATV.0000129331.21092.1d

DO - 10.1161/01.ATV.0000129331.21092.1d

M3 - Article

C2 - 15105283

VL - 24

SP - 1043

EP - 1048

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 6

ER -

Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

Abstract

Access to Document

Fingerprint

Cite this